Nurix Therapeutics (NRIX) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$22.35
+0.6% on the day
+105.8% over 12 months
52-week range $9.18 – $27.79
Share price and insider trades
NRIX closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$4.7M
Insiders buying0
Insiders selling3
Nurix Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 3 sold $4.7M of NRIX stock on the open market.
Get emailed when insiders cluster-buy stocks like NRIX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
NRIX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $134K | 1 |
| Q3 2026 | — | 0 | $1.4M | 13 |
| Q2 2026 | — | 0 | $1.6M | 11 |
| Q1 2026 | — | 0 | $648K | 9 |
| Q4 2025 | — | 0 | $927K | 7 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.2×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Nurix Therapeutics, Inc. insiders reported open-market purchases totaling $0, while 3 insiders reported sales totaling $4.7M. 26 of 41 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 2SEC | Christine RingGeneral Counsel | Sell Plan | 5,7869,110 held (−39%) | $23.19 | $134K | -3.6% | — |
| Sep 2SEC | Christine RingGeneral Counsel | Sell Plan | 5,3879,510 held (−36%) | $25.69 | $138K | -13.0% | — |
| Sep 2SEC | Christine RingGeneral Counsel | Sell Plan | 4009,110 held (−4%) | $26.64 | $11K | -16.1% | — |
| Sep 1SEC | Gwenn HansenChief Scientific Officer | Sell Plan | 1,452117,227 held (−1%) | $25.47 | $37K | -12.2% | — |
| Aug 5SEC | Gwenn HansenChief Scientific Officer | Sell Plan | 4,356117,227 held (−4%) | $25.00 | $109K | -10.6% | — |
| Aug 5SEC | Gwenn HansenChief Scientific Officer | Sell Plan | 2,611117,227 held (−2%) | $24.64 | $64K | -9.3% | — |
| Aug 5SEC | Gwenn HansenChief Scientific Officer | Sell Plan | 1,500119,838 held (−1%) | $23.87 | $36K | -6.4% | — |
| Aug 4SEC | Houte Hans VanCFO | Sell Plan | 2,96740,166 held (−7%) | $24.65 | $73K | -9.3% | — |
| Aug 4SEC | Houte Hans VanCFO | Sell Plan | 1,79443,133 held (−4%) | $23.89 | $43K | -6.4% | — |
| Aug 3SEC | Christine RingGeneral Counsel | Sell Plan | 16,5899,110 held (−65%) | $23.05 | $382K | -3.0% | — |
| Jul 30SEC | Gwenn HansenChief Scientific Officer | Sell | 3,847121,338 held (−3%) | $23.38 | $90K | -4.4% | — |
| Jul 30SEC | Christine RingGeneral Counsel | Sell | 3,84719,912 held (−16%) | $23.38 | $90K | -4.4% | — |
| Jul 30SEC | Houte Hans VanCFO | Sell | 2,84544,927 held (−6%) | $23.38 | $67K | -4.4% | — |
| Jul 2SEC | Christine RingGeneral Counsel | Sell Plan | 11,00813,579 held (−45%) | $23.56 | $259K | -5.1% | — |
| Jun 25SEC | Christine RingGeneral Counsel | Sell Plan | 28,93513,579 held (−68%) | $20.06 | $580K | +11.4% | — |
| Jun 25SEC | Gwenn HansenChief Scientific Officer | Sell Plan | 5,394115,005 held (−4%) | $20.00 | $108K | +11.8% | — |
| Jun 2SEC | Christine RingGeneral Counsel | Sell Plan | 8,14813,579 held (−38%) | $16.60 | $135K | +34.6% | — |
| May 5SEC | Houte Hans VanCFO | Sell Plan | 13,47338,174 held (−26%) | $16.58 | $223K | +34.8% | — |
| May 5SEC | Houte Hans VanCFO | Sell Plan | 58237,592 held (−2%) | $17.18 | $10K | +30.1% | — |
| May 4SEC | Christine RingGeneral Counsel | Sell Plan | 8,14818,305 held (−31%) | $16.96 | $138K | +31.8% | — |
| May 1SEC | Christine RingGeneral Counsel | Sell Plan | 5,39426,453 held (−17%) | $16.76 | $90K | +33.4% | — |
| Apr 30SEC | Gwenn HansenChief Scientific Officer | Sell | 3,214120,399 held (−3%) | $16.65 | $54K | +34.2% | — |
| Apr 30SEC | Christine RingGeneral Counsel | Sell | 3,21431,847 held (−9%) | $16.65 | $54K | +34.2% | — |
| Apr 30SEC | Houte Hans VanCFO | Sell | 2,38851,647 held (−4%) | $16.65 | $40K | +34.2% | — |
| Apr 2SEC | Christine RingGeneral Counsel | Sell Plan | 8,14826,453 held (−24%) | $15.24 | $124K | +46.7% | — |
| Mar 2SEC | Christine RingGeneral Counsel | Sell Plan | 8,14834,601 held (−19%) | $15.44 | $126K | +44.8% | — |
| Feb 9SEC | Christine RingGeneral Counsel | Sell Plan | 14,26142,749 held (−25%) | $16.66 | $238K | +34.2% | — |
| Jan 30SEC | Gwenn HansenChief Scientific Officer | Sell | 4,79783,770 held (−5%) | $16.58 | $80K | +34.8% | — |
| Jan 30SEC | Christine RingGeneral Counsel | Sell | 4,33357,098 held (−7%) | $16.58 | $72K | +34.8% | — |
| Jan 30SEC | Houte Hans VanCFO | Sell | 3,58845,500 held (−7%) | $16.58 | $59K | +34.8% | — |
| Jan 30SEC | Gwenn HansenChief Scientific Officer | Sell | 9883,672 held (−0%) | $17.37 | $2K | +28.7% | — |
| Jan 30SEC | Christine RingGeneral Counsel | Sell | 8857,010 held (−0%) | $17.37 | $2K | +28.7% | — |
| Jan 30SEC | Houte Hans VanCFO | Sell | 7345,427 held (−0%) | $17.37 | $1K | +28.7% | — |
| Jan 20SEC | Christine RingGeneral Counsel | Sell Plan | 3,76050,897 held (−7%) | $18.42 | $69K | +21.3% | — |
| Dec 18SEC | Christine RingGeneral Counsel | Sell Plan | 3,56051,097 held (−7%) | $17.87 | $64K | +25.1% | — |
| Dec 18SEC | Christine RingGeneral Counsel | Sell Plan | 20050,897 held (−0%) | $18.56 | $4K | +20.4% | — |
| Nov 24SEC | Christine RingGeneral Counsel | Sell Plan | 37,60050,897 held (−42%) | $17.07 | $642K | +30.9% | — |
| Nov 3SEC | Houte Hans VanCFO | Sell Plan | 6,28437,592 held (−14%) | $12.56 | $79K | +77.9% | — |
| Oct 30SEC | Gwenn HansenChief Scientific Officer | Sell | 4,08776,751 held (−5%) | $12.80 | $52K | +74.6% | — |
| Oct 30SEC | Christine RingGeneral Counsel | Sell | 3,64450,897 held (−7%) | $12.80 | $47K | +74.6% | — |
| Oct 30SEC | Houte Hans VanCFO | Sell | 3,13043,876 held (−7%) | $12.80 | $40K | +74.6% | — |
Insiders at Nurix Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Christine RingGeneral Counsel | — | $3.4M | Oct 2, 2026 | — |
| Houte Hans VanCFO | — | $635K | Aug 4, 2026 | — |
| Gwenn HansenChief Scientific Officer | — | $631K | Sep 1, 2026 | — |
NRIX stock: common questions
Are Nurix Therapeutics, Inc. insiders buying NRIX stock?
In the past 12 months, 0 insiders reported open-market purchases of NRIX worth $0.
Are Nurix Therapeutics, Inc. insiders selling NRIX stock?
3 insiders reported sales worth $4.7M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is NRIX's 52-week range?
Over the past year NRIX has traded between $9.18 and $27.79. It last closed at $22.35 on Oct 9, 2026.